SCHEMBL23210828

SCHEMBL23210828

Cc1c(I)cccc1CC#N

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
ENPP2 Q13822 1/20 0.34
KDM4E B2RXH2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
IDO1 P14902 2/20 0.31
CSNK2A1 P68400 1/20 0.31
CFTR P13569 1/20 0.31
DYRK1A Q13627 1/20 0.31
GRIA1 P42261 1/20 0.31
CACNG8 Q8WXS5 1/20 0.31
ATP4A P20648 1/20 0.31
ATP4B P51164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28380698 0.87 ALDH1A1 (0.45) ALDH1A1HPGDENPP2KDM4ETDP1
SCHEMBL27158744 0.80 ALDH1A1 (0.38) ALDH1A1HPGDENPP2KDM4ETDP1
SCHEMBL3792645 0.79 ESR1 (0.41) ALDH1A1HPGDENPP2KDM4ETDP1
SCHEMBL533864 0.79 ALDH1A1 (0.47) ALDH1A1HPGDKDM4ETDP1TAAR1
SCHEMBL29385884 0.79 ALDH1A1 (0.47) ALDH1A1HPGDKDM4ETDP1TAAR1
SCHEMBL28195805 0.78 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EPDCD1CD274
SCHEMBL3933757 0.76 TSHR (0.43) ALDH1A1HPGDENPP2
SCHEMBL5200637 0.76 CYP3A4 (0.50) ALDH1A1HPGDENPP2KDM4ETDP1
SCHEMBL11919558 0.76 ALDH1A1 (0.38) ALDH1A1HPGDENPP2TDP1TAAR1
SCHEMBL31454409 0.76 ALDH1A1 (0.38) ALDH1A1HPGDENPP2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 ALDH1A1 559/4885HPGD 790/4885ENPP2 4090/4885
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 ALDH1A1 559/4885HPGD 790/4885ENPP2 4090/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 ALDH1A1 559/4885HPGD 790/4885ENPP2 4090/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 ALDH1A1 559/4885HPGD 790/4885ENPP2 4090/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 ALDH1A1 559/4885HPGD 790/4885ENPP2 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.